• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Catalio Capital Management Launches Credit Opportunities Strategy

    2/2/21 8:17:00 AM ET
    $EXAS
    $CMPS
    $ABCL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EXAS alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Catalio Capital Management, LP (Catalio), a multi-strategy life sciences investment firm, has today announced the launch of their Credit Opportunities strategy to expand the scope of the firm’s investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector.

    The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalized, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Mr. Iucker and Mr. Snyder both joined Catalio from Brown Advisory, an asset management firm with over $100B in AUM, where they played an instrumental role in building Brown’s credit platform.

    In addition to Mr. Iucker and Mr. Snyder, Joshua Samuelson will be joining the Investment Committee of the Credit Opportunities strategy. Mr. Samuelson was a Co-Founder of PointState Capital, a long/short equity and macro-focused fund. At PointState, Mr. Samuelson served as President and managed a diverse portfolio across multiple asset classes until his retirement at the end of 2019. Prior to his time at PointState, he was a Portfolio Manager at Duquesne Capital Management and Soros Fund Management, where, over the course of his career, he focused on convertible bonds, equities and credit.

    Catalio also announced today the appointment of Brandon Matz as the firm’s Head of Marketing & Investor Relations. Mr. Matz is joining Catalio from York Capital Management, a global alternative investment firm with approximately $20B in AUM.

    The launch of the Catalio Credit Opportunities strategy is the latest milestone of many for Catalio, which has grown exponentially since its inception last year. It is now a leading multi-strategy investment firm, with over $450 million in committed capital between both private and public equity strategies.

    George Petrocheilos and Dr. Jacob Vogelstein, Catalio’s Co-Founders & Co-Managing Partners said: “We are delighted to welcome John Henry, Rob, Josh and Brandon to Catalio. The life sciences industry continues to offer significant opportunities for investment, and these latest additions to our team will further augment our platform and help our transformative biomedical technology companies to bring their innovations to market.’’

    Since inception, Catalio has invested in more than 20 prominent high-growth life science companies including AbCellera (NASDAQ: ABCL), COMPASS Pathways (NASDAQ: CMPS) and Thrive Earlier Detection (recently acquired by EXACT Sciences (NASDAQ: EXAS)). The firm closed its oversubscribed second venture fund, Catalio Nexus II, at its hard cap of $100 million in September 2020 and recently announced the launch of HealthCor Catalio Acquisition Corp. (NASDAQ: HCAQ), a special purpose acquisition company, targeting acquisitions in the healthcare industry.

    About Catalio Capital Management L.P.

    Catalio Capital Management, L.P., is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Catalio’s General Partnership includes over 25 world-renowned scientists with extensive academic bona fides who have also started several successful companies based on their research. Catalio has offices in New York, Baltimore, and Washington, DC. For more information, visit www.cataliocapital.com.

    Get the next $EXAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAS
    $CMPS
    $ABCL

    CompanyDatePrice TargetRatingAnalyst
    COMPASS Pathways Plc
    $CMPS
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    Exact Sciences Corporation
    $EXAS
    4/10/2025$60.00Outperform
    Mizuho
    Exact Sciences Corporation
    $EXAS
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    COMPASS Pathways Plc
    $CMPS
    2/27/2025$11.00Buy
    Stifel
    Exact Sciences Corporation
    $EXAS
    1/23/2025$70.00Overweight
    Barclays
    Exact Sciences Corporation
    $EXAS
    8/28/2024$75.00Overweight
    Wells Fargo
    AbCellera Biologics Inc.
    $ABCL
    8/20/2024Buy → Hold
    The Benchmark Company
    COMPASS Pathways Plc
    $CMPS
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $EXAS
    $CMPS
    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • COMPASS Pathways downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded COMPASS Pathways from Outperform to In-line and set a new price target of $6.00 from $11.00 previously

      6/23/25 9:15:38 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Exact Sciences with a new price target

      Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

      4/10/25 12:41:36 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

      RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

      3/13/25 7:36:02 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $CMPS
    $ABCL
    SEC Filings

    See more
    • SEC Form 11-K filed by Exact Sciences Corporation

      11-K - EXACT SCIENCES CORP (0001124140) (Filer)

      6/24/25 4:01:22 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • COMPASS Pathways Plc filed SEC Form 8-K: Other Events

      8-K - COMPASS Pathways plc (0001816590) (Filer)

      6/23/25 6:32:31 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      6/16/25 8:01:00 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $CMPS
    $ABCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Montalbano John S.

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      6/16/25 5:32:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 4 filed by Director Lo Andrew

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      6/16/25 5:30:33 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Doyle James Edward was granted 5,398 shares, increasing direct ownership by 10% to 61,447 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:22 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $CMPS
    $ABCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

      A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 comparing 25 mg to placebo (p<0.001)2 Independent Data Safety Monitoring Board (DSMB) reviewed safety data for COMP360 and found no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo arms Ongoing pivotal Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic3, to report Phase 3 efficacy data Second ongoing pivotal Phase 3 COMP006 trial continues to enroll well, wi

      6/23/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

      ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. The Phase 1 study is anticipated to begin in Q3 of 2025 and will evalu

      5/30/25 1:00:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

      Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer Whole-genome Oncodetect test powered by MAESTRO to launch in 2026 with ultra-low limit of detection1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) t

      5/28/25 6:05:00 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $CMPS
    $ABCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/11/25 6:42:57 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/10/25 5:11:03 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/7/25 3:32:01 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $EXAS
    $CMPS
    $ABCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:35:16 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:20:24 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

      SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

      11/14/24 4:11:49 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care